Genetic and epigenetic of colorectal cancer;Genética y epigenética del cáncer colorrectal

Acta Gastroenterologica Latinoamericana

Volumn 41, Issue 3, 2011, Pages 247-261

  Pellegrini, María Laura ^a   Argibay, Pablo ^a   Gómez, Daniel E ^b  

^a Inst Cie Basicas Y Med E   (Argentina)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Colorectal cancer; Epigenetic; Genomic imprinting; Methylation; Microsatelite instability

Indexed keywords

GENOMIC DNA; SOMATOMEDIN B;

ADENOMATOUS POLYP; ARTICLE; COLON CARCINOGENESIS; COLORECTAL CANCER; DNA METHYLATION; EPIGENETICS; FAMILIAL CANCER; GENE MUTATION; GENOME IMPRINTING; HEREDITARY COLORECTAL CANCER; HUMAN; MICROSATELLITE INSTABILITY; PROMOTER REGION;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P57; EPIGENESIS, GENETIC; FOLIC ACID; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LYMPHOID ENHANCER-BINDING FACTOR 1; MUTATION;

EID: 80053015796     PISSN: 03009033     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Matos EL, Loria DI, Zengarini N. Atlas de Mortalidad por Cáncer de Argentina (1997-2001). Departamento de Carcinogénesis Química y Ambiental. Instituto de Oncología Ángel H Roffo. Buenos Aires, Julio 2003.
2. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, Thibodeau SN. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-3460.
3. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Nat Acad Sci USA 1971;68:820-823.
4. Waddington CH. Introduction to modern genetics. The Mac- Millan Company, 1939.
5. Slack JMW. Conrad Hal Waddington: the last Renaissance biologist? Nature Reviews Genetics 2002;3:889-895.
6. Holliday R. Epigenetics: a historical overview. Epigenetics 2006;1:76-80.
7. Fraga MF, Uriol E, Borja Diego LB, Berdasco M, Esteller M, Cañal MJ, Rodríguez R. High performance capillary electrophoretic method for the quantification of 5-methyl 2'-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues. Electrophoresis 2002; 23:1677-1681.
8. Partha MD, Rakesh S. DNA methylation and cancer. J Clin Oncol 2004;22:4632-4642.
9. Robert JS, Kenichi N, Reinberg D. Histone lysine methylation: a signature for chromatin function. Trends in Genetics 2003;11:629-639.
10. Hu JF, Oruganti H, Vu TH, Hoffman AR. The role of histone acetylation in the allelic expression of the imprinted human insulin-like growth factor II gene. Biochem Biophys Res Commun 1998;20;251:403-408.
11. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-1080.
12. Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 2004;23:29-39.
13. Luedi PP, Dietrich FS, Weidman JR. Computational and experimental identification of novel human imprinted genes. Genome Research 2007;17:1723-1730.
14. Efstratiadis A. Parental imprinting of autosomal mammalian genes. Curr Opin Genet Dev 1994;4:265-280.
15. Constancia M, Pickard B, Kelsey G, Reik W. Imprinting mechanisms. Genome Res 1998;8:881-900.
16. Pollak M. Insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res 2000;10 (Suppl A): S6-S7.
17. Pavelic K, Bukovic D, Pavelic J. The role of insulin-like growth factor 2 and its receptors in human tumors. Mol Med 2002;8:771-780.
18. Sussenbach JS, Steenbergh PH, Jansen E. Structural and regulatory aspects of the human genes encoding IGF-I and -II. Adv Exp Med Biol 1991;293:1-14.
19. Issa JP, Vertino PM, Boehm CD, Newsham IF, Baylin SB. Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci U S A 1996;93:11757-11762.
20. DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991;64:849-859.
21. Giannoukakis N, Deal C, Paquette J, Goodyer CG, Polychronakos C. Parental genomic imprinting of the human IGF2 gene. Nat Genet 1993;4:98-101.
22. Henry I, Bonaiti-Pellie C, Chehensse V. Uniparental paternal disomy in a genetic cancer-predisposing syndrome. Nature 1991;351:665-667.
23. Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M. Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome. Nature 1989;342: 281- 285.
24. Cerrato F, Sparago A, Verde G. Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms tumour. Hum Mol Genet 2008;17:1427-1435.
25. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature 1993;362:747-749.
26. Kinouchi Y, Hiwatashi N, Higashioka S, Nagashima F, Chida M, Toyota T. Relaxation of imprinting of the insulin-like growth factor II gene in colorectal cancer. Cancer Lett 1996;107:105-108.
27. Takano Y, Shiota G, Kawasaki H. Analysis of genomic imprinting of insulin-like growth factor 2 in colorectal cancer. Oncology 2000;59:210-216.
28. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 1998;4: 1276-1280.
29. Kawakami K, Ruszkiewicz A, Bennett G. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 2006;94:593-598.
30. Cui H, Cruz-Correa M, Giardiello FM. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-1755.
31. Ohta M, Sugimoto T, Seto M. Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II. Hum Pathol 2008;39:1301-1308.
32. Cruz-Correa M, Cui H, Giardiello FM. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology 2004;126:964-970.
33. Cruz-Correa M, Zhao R, Oviedo M. Temporal stability and age-related prevalence of loss of imprinting of the insulin-like growth factor-2 gene. Epigenetics 2009;4:114-118.
34. Rachmilewitz J, Goshen R, Ariel I, Schneider T, Groot N, Hochberg A. Parental imprinting of the human H19 gene. FEBS 1992;309:25-28.
35. Brannan CI, Dees EC, Ingram RS, Tilghman SM: The product of the H19 gene may function as RNA. Mol Cell Biol 1990;10:28-36.
36. Kuhn EJ, Geyer PK: Genomic insulators: connecting properties to mechanism. Curr Opin Cell Biol 2003;15:259-265.
37. Moore T, Constancia M, Zubair M, Bailleul B, Feil R, Sasaki H, Reik W. Multiple imprinted sense and antisense transcripts, differential methylation and tandem repeats in a putative imprinting control region upstream of mouse Igf2. Proc Natl Acad Sci USA 1997;94:12509-12514.
38. Taniguchi T, Schofield AE, Scarlett JL, Morison IM, Sullivan MJ, Reeve AE. Altered specificity of IGF2 promoter imprinting during fetal development and onset of Wilms tumour. Oncogene 1995;11:751-756.
39. Ulaner GA, Vu TH, Li T. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 2003;12:535-549.
40. Byun HM, Wong HL, Birnstein EA, Wolff EM, Liang G, Yang AS. Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res 2007;67:10753-10758.
41. Murphy SK, Huang Z, Wen Y. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 2006;4:283-292.
42. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002;62: 6442-6446.
43. Ito Y, Koessler T, Ibrahim AE. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet 2008;17:2633-2643.
44. Pantoja C, de Los Rios L, Matheu A, Antequera F, Serrano M. Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res 2005;65:26-33.
45. De la Chapelle A: Microsatellite instability. N Engl J Med 2003;349:209-210.
46. Alonso A, Moreno S, Valiente A, Artigas M, Perez-Juana A, Ramos Arroyo MA. Genetic mechanisms in the hereditary predisposition to colorectal cancer. An Sist Sanit Navar 2006;29:59-76.
47. Perucho M. Tumors with microsatellite instability: many mutations, targets and paradoxes. Oncogene 2003;22: 2223-2225.
48. Kaz A, Kim YH, Dzieciatkowski S. Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas. Int J Cancer 2007;120:1922-1929.
49. Martina L., Veigl L, Kasturi L, Olechnowicz J, Aihong Ma, Lutterbaugh JD, Periyasamy S, Guo-min Li, Drumond J, Modrich PL, Sedwick WD, Markowitz SD. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998;95:8698-8702.
50. Boland CR, Thibodeau SN, Hamilton SR. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58: 5248-5257.
51. Perucho M. Correspondence re: C.R. Boland et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer (Cancer Res 1998;58:5248-5257). Cancer Res 1999;59:249-256.
52. Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 1997;57:300-303.
53. Lothe RA, Peltomaki P, Meling GI. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993; 53:5849-5852.
54. Nishihara S, Hayashida T, Mitsuya K. Multipoint imprinting analysis in sporadic colorectal cancers with and without microsatellite instability. Int J Oncol 2000; 17:317-322.
55. Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, de La Chapelle A. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci U SA 2001;98: 591-596.
56. Sasaki J, Konishi F, Kawamura YJ, Kai T, Takata O, Tsukamoto T. Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulin-like growth factor 2. Int J Cancer 2006;119:80-83.
57. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-1512.
58. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-649.
59. Reid LH, Crider-Miller SJ, West A, Lee MH, Massague J, Weissman BE. Genomic organization of the human p57KIP2 gene and its analysis in the G401 Wilms' tumor assay. Cancer Res 1996;56:1214-1218.
60. Orlow I, Iavarone A, Crider-Miller SJ. Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors. Cancer Res 1996;56:1219-1221.
61. Hatada I, Mukai T. Genomic imprinting of p57KIP2, a cyclindependent kinase inhibitor, in mouse. Nat Genet 1995;11:204-206.
62. Hatada I, Inazawa J, Abe T. Genomic imprinting of human p57KIP2 and its reduced expression in Wilms tumors. Hum Mol Genet 1996;5:783-788.
63. Cost GJ, Thompson JS, Reichard BA, Lee JY, Feinberg AP. Lack of imprinting of three human cyclin-dependent kinase inhibitor genes. Cancer Res 1997;57:926-929.
64. Matsuoka S, Thompson JS, Edwards MC. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA 1996;93:3026-3030.
65. Thompson JS, Reese KJ, DeBaun MR, Perlman EJ, Feinberg AP. Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms tumor. Cancer Res 1996;56: 5723-5727.
66. Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M, Matsuura N. Expression of p57Kip2 protein in hepatocellular carcinoma. Oncology 2001;61:221-225.
67. Shin JY, Kim HS, Lee KS. Mutation and expression of the p27KIP1 and p57KIP2 genes in human gastric cancer. Exp Mol Med 2000;32:79-83.
68. Lai S, Goepfert H, Gillenwater AM, Luna MA, El-Naggar AK. Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma. Clin Cancer Res 2000;6: 3172-3176.
69. Li JQ, Wu F, Usuki H. Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol 2003;23:1537-1543.
70. Ito Y, Yoshida H, Nakano K. Expression of p57Kip2 protein in normal and neoplastic thyroid tissues. Int J Mol Med 2002;9:373-376.
71. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res 2002;22:3191-3196.
72. Shin JY, Kim HS, Park J, Park JB, Lee JY. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res 2000;60:262-265.
73. Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002;62:3925-3928.
74. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 2004;36:497-501.
75. Hitchins M, Williams R, Cheong K. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology 2005;129:1392-1399.
76. Hitchins MP, Wong JJ, Suthers G. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 2007;356:697-705.
77. Kmet J. The role of migrant population in studies of selected cancer sites: a review. J Chronic Dis 1970;23:305-324.
78. Hubner RA, Houlston RS. Folate and colorectal cancer prevention. Br J Cancer 2009;100:233-239.
79. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res 1988;48:1159-1161.
80. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr 2002;32(Suppl):2350S-2355S.
81. Chen J, Giovannucci E, Kelsey K. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862-4864.
82. Frosst P, Blom HJ, Milos R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
83. Ma J, Stampfer MJ, Giovannucci E. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-1102.
84. Chen J, Giovannucci E, Hankinson SE. A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. Carcinogenesis 1998;19:2129-2132.
85. Pande M, Chen J, Amos CI, Lynch PM, Broaddus R, Frazier M. Influence of methylenetetrahydrofolate reductase gene polymorphisms C677T and A1298C on age-associated risk for colorectal cancer in a caucasian lynch syndrome population. Cancer Epidemiol Biomarkers Prev 2007;16: 1753-1759.
86. Osian G, Procopciuc L, Vlad L. MTHFR polymorphisms as prognostic factors in sporadic colorectal cancer. J Gastrointestin Liver Dis 2007;16:251-256.
87. Shannon B, Gnanasampanthan S, Beilby J, Iacopetta B. A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut 2002;50:520-524.
88. Hubner RA, Lubbe S, Chandler I, Houlston RS. MTHFR C677T has differential influence on risk of MSI and MSS colorectal cancer. Hum Mol Genet 2007;16:1072-1077.
89. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Watanabe G, Iacopetta B. The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 2003;9:5860-5865.
90. Eaton AM, Sandler R, Carethers JM, Millikan RC, Galanko J, Keku TO. 5,10-methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer. Cancer Epidemiol Biomarkers Prev 2005;14:2023-2029.
91. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate- /cobalamin disorders. Human Mol Genet 1996;5:1867-1874.
92. Ma J, Stampfer MJ, Christensen B, Giovannucci E, Hunter DJ, Chen J, Willett WC, Selhub J, Hennekens CH, Gravel R, Rozen R. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8:825-829.
93. Paz MF, Avila S, Fraga MF, Pollan M, Capella G, Peinado MA, Sanchez-Cespedes M, Herman JG, Esteller M. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 2002;62:4519-4524.
94. Matsuo K, Hamajima N, Hirai T, Kato T, Inoue M, Takezaki T, Tajima K. Methionine synthase reductase gene A66G polymorphism is associated with risk of colorectal cancer. Asian Pac J Cancer Prev 2002;3:353-359.
95. Leclerc D, Wilson A, Dumas R, Gafuik C, Song D, Watkins D, Heng HH, Rommens JM, Scherer SW, Rosenblatt DS, Gravel RA. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA 1998; 95:3059-3064.
96. Olteanu H, Munson T, Banerjee R. Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry 2002;41:13378-13385.
97. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML. Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2005;14:2509-2516.